Suppr超能文献

[中线导管在血管活性药物治疗中的临床应用研究]

[Clinical application study of midline catheter in vasopressor therapy].

作者信息

Guo Runling, Wu Jianhua, Ren Xiaoying, Guo Chaoli

机构信息

Department of Respiratory and Critical Care Medicine, Fenyang Hospital, Fenyang 032200, Shanxi, China. Corresponding author: Guo Chaoli, Email:

出版信息

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024 Jul;36(7):760-763. doi: 10.3760/cma.j.cn121430-20240326-00286.

Abstract

OBJECTIVE

To evaluate the safety and necessity of vasopressor infusion through midline catheter.

METHODS

A convenient sampling method was used for a controlled study. A total of 88 adult patients who used vasopressors admitted to respiratory intensive care unit (RICU) of Fenyang Hospital in Shanxi Province from June 2022 to June 2023 were enrolled as the research subjects. A total of 44 patients who were infused with vasopressors through peripherally inserted central venous catheter (PICC) from June to December 2022 were enrolled as the PICC group, and 44 patients who were infused with vasopressors through midline catheter from January to June 2023 were enrolled as the midline catheter group. Both groups of patients used the modified Sedinger technique under the guidance of B-ultrasound for puncture and catheter placement. The middle 1/3 site between the cubital fossa and the axilla was selected. The catheters were 5 Fr double lumen. After catheter placement, the patients were followed until catheter removal, death, or 30 days (whichever came first). Based on the Infusion therapy standards of practice revised by American Infusion Nurses Society (INS), and combined with the results of previous preliminary tests, the safety evaluation was conducted on incomplete catheter obstruction, catheter-related bloodstream infection (CRBSI), phlebitis, thrombus within the catheter during extubation, redness of the puncture site (but no infection), and exudation of the puncture site in the two groups of patients.

RESULTS

There were no statistical differences in gender, age, catheter indwelling time, and primary disease between the two groups, indicating that the baseline data of the two groups were balanced and comparable. No CRBSI or phlebitis occurred in both groups during the observation period after catheterization. One patient in both groups had exudation at the puncture site [both were 2.27% (1/44)]. Compared with the PICC group, the incidence of incomplete catheter obstruction, thrombus within the catheter during extubation, redness of the puncture site (but no infection) in the midline catheter group were lowered [incomplete catheter obstruction: 4.55% (2/44) vs. 6.82% (3/44), thrombus within the catheter during extubation: 0% (0/44) vs. 2.27% (1/44), redness of the puncture site (but no infection): 0% (0/44) vs. 4.55% (2/44)], the overall incidence was significantly decreased [6.82% (3/44) vs. 15.91% (7/44), P < 0.01].

CONCLUSIONS

Administering vasopressor through a midline catheter can reduce the incidence of catheter-related complications, decrease the rate of central venous catheterization, and reduce the financial burden on patients.

摘要

目的

评估通过中线导管输注血管活性药物的安全性和必要性。

方法

采用方便抽样法进行对照研究。选取2022年6月至2023年6月在山西省汾阳医院呼吸重症监护病房(RICU)使用血管活性药物的88例成年患者作为研究对象。将2022年6月至12月通过外周静脉穿刺中心静脉导管(PICC)输注血管活性药物的44例患者作为PICC组,将2023年1月至6月通过中线导管输注血管活性药物的44例患者作为中线导管组。两组患者均在B超引导下采用改良塞丁格技术进行穿刺置管。选择肘窝与腋窝之间的中1/3部位。导管为5 Fr双腔。置管后对患者进行随访,直至导管拔除、死亡或30天(以先到者为准)。依据美国静脉输液护理学会(INS)修订的《输液治疗实践标准》,并结合前期预试验结果,对两组患者的导管堵塞不全、导管相关血流感染(CRBSI)、静脉炎、拔管时导管内血栓、穿刺部位发红(但无感染)及穿刺部位渗液情况进行安全性评估。

结果

两组患者在性别、年龄、导管留置时间及原发病方面比较,差异均无统计学意义,表明两组基线资料均衡、具有可比性。两组患者置管后观察期间均未发生CRBSI及静脉炎。两组各有1例患者穿刺部位渗液[均为2.27%(1/44)]。与PICC组比较,中线导管组导管堵塞不全、拔管时导管内血栓、穿刺部位发红(但无感染)的发生率均降低[导管堵塞不全:4.55%(2/44)比6.82%(3/44),拔管时导管内血栓:0%(0/44)比2.27%(1/44),穿刺部位发红(但无感染):0%(0/44)比4.55%(2/44)],总体发生率显著降低[6.82%(3/44)比15.91%(7/44),P<0.01]。

结论

通过中线导管输注血管活性药物可降低导管相关并发症的发生率,减少中心静脉置管率,减轻患者经济负担。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验